HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

ARAY

Accuray Incorporated (NASDAQ)

Healthcare — Medical Devices

Accuray Incorporated engages in the design, development, manufacture, and sale of radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. It also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, the company offers post-contract customer support, installation, training, and other professional services. It primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.

None 1 analysts
$0.26
$0.00 (-0.85%)
Target: $0.35 (35.8%)
Sign in to add ARAY to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$30.67M
P/E Ratio (TTM)-
Forward P/E-1.07
EPS (TTM)$-0.38
Dividend Yield-
Profit Margin-10.76%
Revenue Growth-7.40%
ROE-101.06%
Debt/Equity437.33
Recommendation None
Analyst Target$0.35
Analysts1
Indexes NASDAQ

Technical Indicators

RSI (14)31.2
Beta1.35
SMA 20-
SMA 40-
52-Week High$2.10
52-Week Low$0.25
50-Day Avg$0.37
200-Day Avg$0.82
Avg Volume$3.44M
Volume$1.21M

Performance Analysis

NEUTRAL

ARAY presents a mixed picture with both positive and negative indicators.

+ Trading near its 52-week low ($0.25), which could present a value opportunity.
~ RSI at 31.2 is in neutral territory.
- Price is below both the 50-day and 200-day moving averages — in a downtrend.
- Revenue declined 7.4% year-over-year.
- Operating at a loss with -10.8% margin.
~ Wall Street consensus is "none" from 1 analysts.
+ Average analyst target of $0.35 implies 35.8% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jun 30, 2026 21:07 UTC

Back to Screener Export Report